Biocatalysts Ltd

Biocatalysts Limited does not publish investor-style five-year financials. The entity-level table uses the two years that could be confirmed. "n/d" means not publicly disclosed in the sources consulted. The full income statement, cash flow statement and notes are in the group accounts PDF at Companies House.

6.1 Entity level: Biocatalysts Limited group accounts (GBP million, years to 30 September). Source: Endole summary of filed accounts. FY2023 values are derived from Endole's stated year-on-year changes.

Gross profit, operating income, EBITDA, pre-tax income, net income, debt split, goodwill, working capital, operating cash flow, capex and dividends are not publicly disclosed in the sources consulted. EPS and buybacks are not applicable to a wholly owned private subsidiary.

Commentary. The 76% rise in turnover in FY2024 is mainly a consolidation effect. Breatec, WeissBioTech and Biosun were bought from the parent in November 2023 and so contributed about ten months to FY2024. It should not be read as organic growth. The only long-run reference point is FY2016/17 revenue of about GBP 9.5 million. Liabilities are about two-thirds of total assets, consistent with an intra-group funded acquisition and the fermentation capacity build-out. A new charge was registered in August 2024.

6.2 Parent level: BRAIN Biotech AG consolidated (EUR million, years to 30 September). FY2024 and FY2025 are from the 14 January 2026 release.

The parent pays no dividend, and no buyback is known.

Commentary. Three points matter for Biocatalysts Ltd. First, the enzyme segment is profitable at the adjusted EBITDA level (EUR 4.4 million in FY2024/25) while the group is not, because holding costs and the incubator absorb the contribution. Second, group cash fell from EUR 27.2 million to EUR 6.2 million during FY2024/25 as debt was repaid and the Dutch site was built, and stood at EUR 0.9 million on 30 June 2026 alongside a EUR 9.0 million revolving credit line. Third, management cited a US dollar about 14% weaker than planned as a large part of the FY2024/25 revenue shortfall in the segment, which shows meaningful dollar exposure.

Management guidance. For FY2025/26 the parent expects enzyme segment revenue below EUR 45.4 million and an adjusted EBITDA margin below 10%, with group adjusted EBITDA around break-even. The five-year target of EUR 100 million and a 15% margin has not been withdrawn.

Consensus. There is no consensus for Biocatalysts Ltd. For the parent, MarketScreener shows a Buy rating with a target of EUR 5.50 against a price of about EUR 2.85.

Bull case

1. The enzyme business is profitable on its own. With holding costs under control and the incubator now contributing, group break-even is within reach.

2. Heavy investment is largely complete: the second fermenter, the Cardiff upgrades and the Dutch hub are in place, so capital needs should fall and synergies should follow.

3. The incoming CEO ran a global enzyme business at BASF and inherits a platform that was repositioned as an integrated enzyme manufacturer.

Bear case

1. Revenue in the enzyme segment has fallen for two consecutive periods, and the 13.3% decline in the first nine months of FY2025/26 is too large to explain by comparison effects alone.

2. Parent cash of EUR 0.9 million leaves little room for error and raises the probability of a dilutive capital raise or an asset sale, either of which could change the ownership or funding of Biocatalysts Ltd.

3. Margin has halved to about 5%, well below the 15% target, while larger competitors hold pricing power.

Catalysts and monitorables for the next 12 months

• Filing of the Biocatalysts Limited accounts for the year to 30 September 2025.

• BRAIN's FY2025/26 results and FY2026/27 guidance, expected around January 2027.

• Dr Weber's first strategic statement and any revision of the EUR 100 million target.

• Recovery in baking enzyme sales once the Dutch site is running normally.

• Parent financing actions: credit line usage, capital increase or disposals.

• Changes to the Biocatalysts Limited board after Mr Moelker's departure.

• Dollar to euro and sterling exchange rates.

Analyst verdict. Biocatalysts Ltd. is not a public company, and the starting point for any work on it should be that correction. It is a 43-year-old Welsh specialty enzyme manufacturer, wholly owned by BRAIN Biotech AG, and since late 2023 the legal owner of the group's Dutch, German and US enzyme businesses. That reorganisation explains the jump in turnover to GBP 36.2 million in FY2024 and should not be mistaken for organic growth.

The business has real assets. It has its own fermentation capacity, a recognised catalogue in protein and lipid modification, a credible custom development service, and a new continental production hub. The enzyme segment it anchors earned EUR 4.4 million of adjusted EBITDA in FY2024/25.

The direction of travel is the concern. Segment revenue fell 4.4% in FY2024/25 and 13.3% in the first nine months of FY2025/26. Margin dropped from about 10% to about 5%. Guidance was cut twice. The business ran for eight months without a dedicated head. The parent's cash fell from EUR 27.2 million to under EUR 1 million in 21 months. Some of this is temporary: relocation disruption, a strong prior-year quarter and currency. The baking weakness and the cost base built for growth that did not arrive are less clearly temporary.

The appointment of a former BASF enzyme executive as parent CEO is the most important near-term variable. He inherits completed capital projects and a strained balance sheet. The plausible outcomes range from a recovery led by better commercial execution to a refinancing or strategic transaction at parent level.

For a counterparty, supplier or adviser, Biocatalysts Ltd. is an operationally sound specialist whose risk profile is set mainly by its parent.

---

SOURCES CONSULTED

• Companies House: Biocatalysts Limited (02570883) overview, officers and filing history

• Endole: Biocatalysts Limited company profile (summary of filed accounts)

• North Data and CompanyCheck: director history and LEI

• Biocatalysts Ltd website: home page, product navigation, media and resources, life science solutions

• BRAIN Biotech AG press releases: 2018 share purchase; 17 Dec 2019 capacity expansion; May 2021 stake increase; 12 Dec 2024 segment change; 3M, 6M and 9M FY2024/25; 20 May 2025 Breatec; 14 Jan 2026 FY2024/25; 29 Jul 2026 CEO appointment; 27 Aug 2026 9M FY2025/26

• Blake Morgan: 2018 transaction note

• Insider Media: 27 Nov 2023 acquisitions

• Morningstar, MarketScreener, Stockopedia: parent share data

• PitchBook, Crunchbase, Dealroom, LeadIQ: company profiles (aggregators; used with caution)

• Coherent Market Insights, Mordor Intelligence, Polaris Market Research: market estimates and product launch references